Moleculin Biotech, INC 8-K filings

Moleculin Biotech, Inc. stockholders approved the issuance of shares related to warrants but rejected a proposed name change to Moleculin Inc. at a Special Meeting.

Moleculin Biotech, Inc. announced it is using an investor presentation dated January 2026, available on its website.

Moleculin Biotech announced an independent assessment confirmed Annamycin consistently demonstrates no evidence of cardiotoxicity across five clinical trials in 90 subjects.

Moleculin Biotech announces accelerated 2026 outlook, including first pivotal trial unblinding, global expansion, and new externally funded clinical programs for Annamycin and WP1066.

Moleculin Biotech, Inc. announced it has regained compliance with Nasdaq's minimum stockholders' equity requirement, leading to the cancellation of its delisting hearing.

Moleculin Biotech, Inc. announced warrant amendments and capital raises, significantly improving its stockholders' equity to over $10 million, addressing Nasdaq listing compliance.

Moleculin Biotech announced positive Phase 1 clinical trial results for WP1066 in pediatric recurrent malignant brain tumors, demonstrating safety and anti-tumor immune responses.

Moleculin Biotech, Inc. announced it has regained compliance with Nasdaq's minimum bid price requirement, closing the previously reported deficiency.

Moleculin Biotech, Inc. secured approximately $6.8 million in gross proceeds by inducing holders of existing Series C, D, and F warrants to exercise them in exchange for new Series G warrants.

Moleculin Biotech reports 78% enrollment for its pivotal MIRACLE Phase 2B/3 Annamycin study in R/R AML, with first unblinding expected in Q1 2026.

Moleculin Biotech announces a new collaboration with CIC biomaGUNE to conduct investigator-initiated preclinical research on Annamycin for glioblastoma multiforme, a severe form of brain cancer.

Moleculin Biotech, Inc. will implement a 1-for-25 reverse stock split effective December 1, 2025, to consolidate shares and maintain its Nasdaq listing.

Moleculin Biotech, Inc. announced the posting of its latest corporate investor presentation on its company website.

Moleculin Biotech, Inc. received a delist determination from Nasdaq for failing to meet minimum stockholders' equity requirements but plans to appeal.

Moleculin Biotech announced 60% enrollment for the first interim unblinding of its pivotal Phase 2B/3 MIRACLE study of Annamycin for relapsed/refractory AML, with initial data expected in Q1 2026.

Moleculin Biotech, Inc. announced a research agreement with the University of North Carolina at Chapel Hill to evaluate Annamycin for pancreatic cancer treatment.

Moleculin Biotech, Inc. announced it has posted its updated corporate investor presentation on its website.

Moleculin Biotech announced the grant of an Australian patent for its Annamycin drug candidate, enhancing its global intellectual property portfolio.

Moleculin Biotech announced a new investigator-initiated Phase 1B/2 study of Annamycin for third-line advanced pancreatic cancer with Atlantic Health.

Moleculin Biotech, Inc. stockholders approved the issuance of shares for warrants but did not approve a corporate name change at a recent Special Meeting.

Moleculin Biotech, Inc. announced a notice of allowance for a Canadian patent covering its Annamycin drug candidate, strengthening its global intellectual property portfolio.

Moleculin Biotech announced accelerated recruitment and global expansion for its pivotal Phase 3 MIRACLE clinical trial of Annamycin for relapsed or refractory acute myeloid leukemia.

Moleculin Biotech, Inc. announced the posting of its latest corporate investor presentation on its company website.

Moleculin Biotech announced the enrollment of the first two subjects and treatment of one in the EU for its pivotal Phase 2B/3 MIRACLE trial for relapsed or refractory Acute Myeloid Leukemia (R/R AML).

Moleculin Biotech secured approximately $6.0 million in gross proceeds by inducing existing warrant holders to exercise their warrants, issuing new Series F warrants in return.

Moleculin Biotech increased authorized common stock and announced positive overall survival data from its Phase 1B/2 Annamycin AML clinical trial.

Moleculin Biotech, Inc. has filed an 8-K to furnish its latest corporate investor presentation, available on its website.

Moleculin Biotech, Inc. stockholders approved director elections, auditor ratification, executive compensation, and significant share authorizations for warrants and future capital needs, while rejecting a supermajority voting change.

Moleculin Biotech, Inc. announced its second quarter 2025 financial results, highlighting significant progress in its MIRACLE trial for AML and positive topline data for Annamycin in STS lung metastases, while facing increased net loss and a short cash runway.

Moleculin Biotech announces encouraging preclinical data for Annamycin demonstrating significant efficacy against various primary and metastatic liver cancers.